Skip to main content

Research Repository

Advanced Search

Dr CHRISTOPHER COLEMAN's Outputs (2)

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients (2020)
Journal Article
Funnell, S. G., Dowling, W. E., Muñoz-Fontela, C., Gsell, P. S., Ingber, D. E., Hamilton, G. A., Delang, L., Rocha-Pereira, J., Kaptein, S., Dallmeier, K. H., Neyts, J., Rosenke, K., de Wit, E., Feldmann, H., Maisonnasse, P., Le Grand, R., Frieman, M. B., & Coleman, C. M. (2020). Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. Nature Communications, 11(1), https://doi.org/10.1038/s41467-020-17907-w

Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV (2020)
Journal Article
Weston, S., Coleman, C. M., Haupt, R., Logue, J., Matthews, K., Li, Y., Reyes, H. M., Weiss, S. R., & Frieman, M. B. (2020). Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV. Journal of Virology, 94(21), Article 10.1128/jvi.01218-20. https://doi.org/10.1128/jvi.01218-20

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China at the end of 2019 and has rapidly caused a pandemic, with over 20 million recorded COVID-19 cases in August 2020 (https://covid19.who.int/). There are no FDA-approved anti... Read More about Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV.